ABCL-1492: Mosunetuzumab Plus Polatuzumab Vedotin (MPola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO TrialJason R. Westin, Michael C. Wei, Huilai Zhang et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
ORAL ABSTRACT: ABCL-1492 Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO TrialJason R. Westin, Won-Seog Kim, Laura Maria Fogliatto et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0